Safety and Efficacy Study of CF101 to Treat Psoriasis

Inclusion Criteria: * Male or female, 18 to 70 years of age, inclusive; * Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area involvement ≥10%, as judged by the Investigator; * Duration of psoriasis of at least 6 months; * PASI score ≥10; * Body weight ≤100 kg; * Candidate for systemic treatment or phototherapy for psoriasis; * ECG is normal or shows abnormalities which, in the judgment of the Investigator, are not clinically significant; * Females of child-bearing potential must have a negative serum pregnancy test at screening; * Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the Investigator (for example oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study; * Ability to complete the study in compliance with the protocol; and * Ability to understand and provide written informed consent. Exclusion Criteria: * Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis; * Treatment with systemic retinoids, corticosteroids, or immunosuppressants (e.g., methotrexate, cyclosporine) within 6 weeks of the Baseline visit; * Treatment with high potency topical corticosteroids (Class I-III), keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit; * Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period; * Treatment with a biological agent (including etanercept, adalimumab, efalizumab, infliximab, or alefacept) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit; * History of poor clinical response to methotrexate after an adequate regimen and duration of treatment; * Treatment with systemic nonsteroidal anti-inflammatory drugs, beta-blockers, lithium, hydroxychloroquine, chloroquine, or systemic terbinafine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period; * Presence or history of uncontrolled asthma; * Presence or history of uncontrolled arterial hypertension or symptomatic hypotension; * Significant cardiac arrhythmia or conduction block, congestive heart failure (New York Heart Association Class 3-4), or any other evidence of clinically significant heart disease or clinically significant findings on screening electrocardiogram; * Hemoglobin level \<9.0 gm/L; * Platelet count \<125,000/mm\^3; * White blood cell count \<3500/mm\^3; * Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal; * Liver aminotransferase levels greater than 2 times the laboratory's upper limit of normal; * Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the Investigator; * History of malignancy within the past 5 years (excluding basal cell carcinoma of the skin and ≤3 cutaneous squamous cell carcinomas, all of which have been completely excised); * Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study; * Participation in another investigational drug or vaccine trial concurrently or within 30 days; or within 5 half lives of a biological investigational product, whichever is longer; * Other conditions which would confound the study evaluations or endanger the safety of the patient.